Company
ChitogenX Inc
CNSX: CHGX
ChitogenX Inc. (formally Ortho Regenerative Technologies Inc.) is a publicly traded (CSE: CHGX, OTCQB: CHNXF) clinical stage regenerative medicine company dedicated to the development of novel therapeutic tissue repair technologies to improve tissue healing. The Company name change better reflects the breadth of potential clinical and commercial applications for our proprietary chitosan-based biopolymer and biologic combination.
21 stories
ChitogenX successfully completes the initial portion of its US Phase I/II rotator cuff repair clinical trial
The Montreal-based regenerative medicine company said there were no safety issues and no adverse events reported in the initial portion of the clinical trial
ChitogenX announces partnership with California Medical Innovations Institute
The first focus of the partnership will evaluate whether ChitogenX lyophilised chitosan matrix, combined with platelet rich plasma or other biologics can improve healing of a range of tissues germane to common surgical practice
ChitogenX shares jump on launch of its second orthopedic development program in meniscus repair
"The meniscus preclinical study will be our second proof of concept for our proprietary ORTHO-R drug/biologic product in an orthopedic indication with high unmet medical needs," said company CEO Philippe Deschamps